Congress extends pharma pricing shield, delaying Medicare drug negotiations
H.R. 1492 — To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. · Filed by Gregory Murphy (R-NC) · 68 cosponsors · Introduced Feb 21, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends the period during which biologic drugs are protected from Medicare price negotiation from 7 years to 11 years, matching the protection period for small-molecule drugs. Biologic manufacturers gain a longer window before their prices can be negotiated by Medicare, while Medicare and taxpayers face higher drug costs for a longer period.
Why we flagged it
The bill's sole operative effect is to extend the period during which biologic drug manufacturers are shielded from Medicare price negotiation. This is a direct extension of market protection for a specific industry segment.
What the text implies
- The 11-year period now matches small-molecule drugs, but biologics typically have higher per-unit costs and longer market lifecycles, so the extended protection may have outsized fiscal impact on Medicare spending.
- The retroactive effective date ('as if included in the enactment of Public Law 117–169') may affect the calculation of exclusion periods for biologics already in the market, potentially extending protections for drugs already approved.
- By equalizing the periods, the bill removes a policy distinction that may have been intentional — biologics were given shorter protection, possibly reflecting their different development timelines or cost structures.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary citizens and Medicare beneficiaries face higher drug costs for a longer period. The bill extends manufacturer pricing power by 4 years, delaying the point at which Medicare can negotiate lower prices for biologic drugs, directly increasing out-of-pocket costs and program expenditures.
Who stands to gain
- biologic pharmaceutical manufacturers
- large-cap pharma companies with biologic portfolios
Named in the bill
Social Security Act, Drug Price Negotiation Program, Medicare, biologic drugs, small-molecule drugs, Public Law 117–169
Where it stands
68 cosponsors: 64 Republicans, 4 Democrats.
- Feb 21, 2025 — Introduced · Congress.gov: “Introduced in House”
- Feb 21, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
46 lobbying clients named this bill on 65 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $44,422,577 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 99% of bills with at least one filing.
Gregory Murphy, the sponsor, reported $1,068,698 in PAC receipts in the 2026 cycle. $34,000 of that came from 7 PACs tied to these lobbying clients.
- Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
- AARP — $5,300,000 on 1 filing
- Bristol-myers Squibb Company — $3,160,000 on 1 filing
- Amgen Inc — $2,440,000 on 1 filing
- Biotechnology Innovation Organization — $2,360,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (375 characters) on Jun 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress extends pharma pricing shield, delaying Medicare drug negotiations” QuorumCivic. https://share.quorumcivic.app/bill/119/hr1492 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.